Determination of prevalence and features of HRRm mCRPC (ADAM)

Trial Identifier: D133HR00008
Sponsor: AstraZeneca
NCTID:: NCT04712890
Start Date: October 2020
Primary Completion Date: September 2022
Study Completion Date: September 2022

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Russia, Altai Krai Barnaul, Altai Krai, Russia
Russia, Chelyabinsk Region Chelyabinsk, Chelyabinsk Region, Russia
Russia, Krasnoyarsk Krai Krasnoyarsk, Krasnoyarsk Krai, Russia
Russia, Leningrad Region Saint Petersburg, Leningrad Region, Russia
Russia, Moscow Moscow, Russia
Russia, Nizhniy Novgorod Region Nizhniy Novgorod, Nizhniy Novgorod Region, Russia
Russia, Omsk Region Omsk, Omsk Region, Russia
Russia, Primorsky Krai Vladivostok, Primorsky Krai, Russia
Russia, Republic of Bashkortostan Ufa, Republic of Bashkortostan, Russia
Russia, Saint Petersburg Saint Petersburg, Russia
Russia, Sakhalin Region Yuzhno-Sakhalinsk, Sakhalin Region, Russia
Russia, Sverdlovsk Region Yekaterinburg, Sverdlovsk Region, Russia
Russia, Tyumen Region Tyumen, Tyumen Region, Russia
Russia, Yaroslavl Region Yaroslavl, Yaroslavl Region, Russia